Treatment for MDS/MPN Overlap Syndrome
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two drugs (azacitidine or ruxolitinib plus selinexor) for people with MDS/MPN overlap syndrome, a type of blood cancer. It aims to see if this treatment helps control symptoms and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of MDS/MPN overlap syndrome (a specific blood cancer) that needs treatment because of symptoms like low blood counts, an enlarged spleen, or feeling very tired.
- You must have good liver and kidney function, and be able to walk and care for yourself (ECOG score 0-2).
- You cannot have had your spleen removed, or have active infections, serious heart problems, or other active cancers.
- You must not have evidence of acute leukemia (more than 20% blast cells in your bone marrow or blood).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, selinexor and venetoclax, given after a stem cell transplant to keep high-risk leukemia or myelodysplastic syndrome from coming back. The goal is to see if this maintenance therapy is safe and effective for patients.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This trial tests a three-drug combination (selinisole, azacitidine, and venetoclax) for newly diagnosed high-risk blood cancers with a TP53 gene change. These drugs aim to target the cancer while skipping standard chemotherapy, possibly making treatment more effective and less harsh.
This early-phase trial studies a new treatment plan (decitabine-related medicine with other targeted drugs, depending on the arm) for adults with MDS/MPN overlap syndromes. It aims to improve control of the disease by targeting the abnormal bone marrow cells. Because it’s Phase 1/2, the main goal is to find safe dosing and see whether it helps responses.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.